{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:53:05Z","timestamp":1771555985605,"version":"3.50.1"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,3,15]]},"DOI":"10.2169\/internalmedicine.1874-18","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T18:30:46Z","timestamp":1539714646000},"page":"791-795","source":"Crossref","is-referenced-by-count":16,"title":["Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma"],"prefix":"10.2169","volume":"58","author":[{"given":"Masashi","family":"Hirooka","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Ochi","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Gastroenterology Center, Ehime Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bunzo","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Joko","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Michitaka","sequence":"additional","affiliation":[{"name":"Gastroenterology Center, Ehime Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52: 512-519, 2017.","DOI":"10.1007\/s00535-016-1263-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459-5465, 2008.","DOI":"10.1158\/1078-0432.CCR-07-5270"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014: 638747, 2014.","DOI":"10.1155\/2014\/638747"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6: 18, 2014.","DOI":"10.1186\/2045-824X-6-18"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372: 621-630, 2015.","DOI":"10.1056\/NEJMoa1406470"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16: 1473-1482, 2015.","DOI":"10.1016\/S1470-2045(15)00290-9"},{"key":"7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"7. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391: 1163-1173, 2018.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52: 512-519, 2017.","DOI":"10.1007\/s00535-016-1263-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lechner MG, Vyas CM, Hamnvik OR, et al. Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced nonthyroidal cancer patients. Thyroid 28: 437-444, 2018.","DOI":"10.1089\/thy.2017.0579"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ohba K, Takayama T, Matsunaga H, et al. Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid 23: 443-448, 2018.","DOI":"10.1089\/thy.2012.0378"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369: 722-731, 2013.","DOI":"10.1056\/NEJMoa1303989"},{"key":"12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/thy.2010.0234","volume":"21","author":"L van Doorn","year":"2011","unstructured":"12. van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 21: 197-202, 2011.","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sakurai K, Fukazawa H, Arihara Z, Yoshida K. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med 222: 39-44, 2010.","DOI":"10.1620\/tjem.222.39"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145: 660-664, 2006.","DOI":"10.7326\/0003-4819-145-9-200611070-00008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sato S, Muraishi K, Tani J, et al. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J 57: 873-880, 2010.","DOI":"10.1507\/endocrj.K10E-130"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Sch\u00f6ffski P. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 20: 317-322, 2010.","DOI":"10.1089\/thy.2009.0125"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/6\/58_1874-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T01:49:44Z","timestamp":1552700984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/6\/58_1874-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1874-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]}}}